Semaglutide vs Tirzepatide: Weight Loss, Lean Mass, and Which GLP-1 Works Best

You're considering a GLP-1 medication for weight management, and the question everyone asks: Ozempic/Wegovy (semaglutide) or Mounjaro/Zepbound (tirzepatide)?

The 2024 meta-analysis data is in, and the numbers are striking. But weight loss percentage alone doesn't tell the whole story. Lean mass preservation, side effect profiles, and long-term outcomes matter just as much—maybe more—than what the scale says.

Here's what the research actually shows.

Weight Loss Efficacy Findings

According to the new systematic review and meta-analysis by Müllertz et al. (2024), both semaglutide and tirzepatide demonstrate significant efficacy in non-diabetic patients with obesity:

‍

Semaglutide (2.4mg weekly):

Average weight loss: -12.9% vs placebo (Müllertz et al., 2024)

Waist circumference reduction: -9.7cm

Supporting data from STEP trials (Wilding et al., 2021; Garvey et al., 2022)

‍

Tirzepatide (10/15mg weekly):

Average weight loss: -19.2% vs placebo (Müllertz et al., 2024)

Waist circumference reduction: -14.6cm

Corroborated by SURMOUNT trials (Jastreboff et al., 2022; Wadden et al., 2023)

‍

Body Composition Analysis

Key findings from subpopulation analyses in the STEP 1 and SURMOUNT-1 trials revealed:

Semaglutide: ~39% of total weight loss from lean mass (Wilding et al., 2021)

Tirzepatide: Total fat mass reduced by 34%, lean mass by 11% (Jastreboff et al., 2022)

‍

Clinical Implications

‍

Safety Profile (Müllertz et al., 2024):

Semaglutide: 91% experienced at least one adverse event

Tirzepatide: 81.5% experienced at least one adverse event

Predominantly gastrointestinal side effects, diminishing after initial titration

‍

Long-term Considerations:

Weight regain of approximately two-thirds after discontinuation (Wilding et al., 2022)

Exercise combination shows superior outcomes in lean mass preservation (Lundgren et al., 2021)

Cardiovascular benefits now established (Lincoff et al., 2023)

Future Directions

Current research developments include:

Higher dose semaglutide (7.2mg) in STEP UP trial (Clinical Trials ID: NCT05646706)

Oral semaglutide showing 15.1% weight loss (Knop et al., 2023)

CagriSema combination therapy development (Enebo et al., 2021)

‍

Clinical Practice Recommendations

Based on the current evidence:

1. Initiate treatment in appropriate BMI categories (≥30 or ≥27 with comorbidities) (Müllertz et al., 2024)

2. Implement concurrent exercise program (Lundgren et al., 2021)

3. Monitor closely during titration for side effect management (Müllertz et al., 2024)

4. Counsel on long-term treatment necessity (Wilding et al., 2022)

This comprehensive meta-analysis represents a significant advancement in our understanding of medical weight management options, with efficacy approaching bariatric surgery results (Sjöström et al., 2007). However, success requires an integrated approach combining pharmacotherapy with lifestyle modifications and careful monitoring.

---

The Bottom Line

• Weight Loss: -12.9% vs placebo — -19.2% vs placebo
• Waist Reduction: -9.7 cm — -14.6 cm
• Lean Mass Loss: ~39% of total loss — ~11% of total loss
• Side Effects: 91% experience any AE — 81.5% experience any AE
• Mechanism: GLP-1 only — GLP-1 + GIP dual agonist

Key takeaways:

• Tirzepatide produces greater weight loss with potentially better lean mass preservation
• Both medications show weight regain of approximately two-thirds after discontinuation—long-term use is typically necessary
• Exercise is essential for preserving lean mass regardless of which medication you choose
• Side effects are predominantly GI and tend to diminish after the initial titration period

The "best" choice depends on your individual factors: cardiovascular history, cost/insurance coverage, side effect tolerance, and treatment goals.

---

Considering GLP-1 Therapy for Weight Management?

A comprehensive evaluation helps determine if you're a good candidate and which medication aligns with your goals and health profile.

What to expect:

• Thorough medical history and metabolic assessment

• Discussion of both medications, including realistic expectations
• Lab workup to establish baseline and monitor progress
• Guidance on exercise and nutrition to maximize lean mass preservation

Investment: Initial evaluation and follow-ups covered by most insurance plans (cash rates: $350-450 initial, $150-200 follow-ups; sliding scale available for uninsured).

Locations: Psychiatric evaluation in Rancho Palos Verdes, Psychiatric evaluation in Phoenix, Psychiatric evaluation in Chandler, and telehealth throughout California and Arizona

Book Your Consultation →

---

Disclaimer: This article is for educational purposes only and does not constitute medical advice. GLP-1 agonists are prescription medications with specific indications, contraindications, and potential side effects. Medication selection should be made in consultation with a qualified healthcare provider who can evaluate your individual health status, treatment goals, and potential drug interactions. Weight management medications work best as part of a comprehensive approach including nutrition and exercise.

---

References

Enebo, L. B., Berthelsen, K. K., Kankam, M., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet, 397(10286), 1736-1748.

Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091.

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.

Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 402(10403), 705-719.

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232.

Lundgren, J. R., Janus, C., Jensen, S. B. K., et al. (2021). Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine, 384(18), 1719-1730.

Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024). Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity Reviews, 25(5), e13717.

Sjöström, L., Narbro, K., Sjöström, C. D., et al. (2007). Effects of bariatric surgery on mortality in Swedish obese subjects. New England Journal of Medicine, 357(8), 741-752.

Wadden, T. A., Chao, A. M., Machineni, S., et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine, 29(11), 2909-2918.

Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564.

‍